Zegbeh Jallah
Stock Analyst at Capital One
(2.97)
# 1,415
Out of 4,784 analysts
25
Total ratings
34.78%
Success rate
111.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $1.32 | +7,475.76% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.22 | +5,399.54% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $5.83 | +654.72% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $2.91 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $17.05 | +70.09% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $1.22 | +3,834.43% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $5.71 | +1,125.92% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $2.93 | +616.72% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $7.59 | +1,678.66% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.88 | +4,483.33% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.80 | +650.47% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $11.93 | +361.02% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.91 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.95 | +742.11% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.25 | +7,900.00% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $1.32
Upside: +7,475.76%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.22
Upside: +5,399.54%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $5.83
Upside: +654.72%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $2.91
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $17.05
Upside: +70.09%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $1.22
Upside: +3,834.43%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $5.71
Upside: +1,125.92%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $2.93
Upside: +616.72%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $7.59
Upside: +1,678.66%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.88
Upside: +4,483.33%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.80
Upside: +650.47%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $11.93
Upside: +361.02%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.91
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.95
Upside: +742.11%
Dec 18, 2019
Initiates: Buy
Price Target: $20
Current: $0.25
Upside: +7,900.00%